NCT03339843 - Multiorgan Metabolic Imaging Response Assessment of Abemaciclib | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 19, 2018

Primary Completion Date

November 12, 2021

Study Completion Date

December 20, 2023

Conditions

Esophageal AdenocarcinomaEsophagus SCCCholangiocarcinomaUrothelial/Bladder Cancer, NosEndometrial Cancer

Interventions

DRUG

Abemaciclib

Subjects will receive 200 mg of abemaciclib orally, two times a day, during cycles of 28 days each. An early FDG-PET/CT will be performed at cycle 1 day 14 to search for any new lesions.

Trial Locations (11)

1000

Institut Jules Bordet, Brussels

4000

CHC Saint-Joseph, Liège

5000

CHU UCL Namur Sainte-Elisabeth, Namur

7000

CHU Ambroise Paré, Mons

8500

Algemeen Ziekenhuis Groeninge, Kortrijk

13009

Institut Paoli-Calmettes, Marseille

31059

IUCT Oncopole - Institut Claudius Regaud, Toulouse

59000

Centre Oscar Lambret, Lille

67000

Hôpital universitaire de Strasbourg - ICANS, Strasbourg

76038

Centre Henri Becquerel, Rouen

Unknown

Universitair Ziekenhuis, Antwerp